newsfilter
← Latest News
Business Wire·

ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or